EUCTR2019-002871-32-PL进行中（未招募）1 期
A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab for Eosinophilic Esophagitis (MESSINA) - MESSINA
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 170
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Patients 12 to 65 years of age, inclusive, at the time of signing the
- •informed consent or assent (if applicable) form.
- •-Documented previous diagnosis of EoE by endoscopy (documented
- •diagnosis defined as an esophageal count of =15 eos/hpf on at least 1
- •XML File Identifier: L9b6uobKOJzSkjr7DnEP/7me/Ps=
- •esophageal level) and confirmed diagnosis by a centrally-read
- •esophageal biopsy for the purposes of this study (confirmed diagnosis
- •defined as an esophageal count of =15 eos/hpf at 2 or more esophageal
- •Two to 4 biopsies should be obtained from both the proximal and distal
- •Biopsies can be taken from the mid-esophagus for additional evaluation.
- •-Must be symptomatic at Visit 1 (screening) and Visit 2 (randomization):
- •(a) A patient reported average of at least 2 days per week with an
- •episode of dysphagia over the 4 weeks prior to Visit 1 AND
- •(b) At least 2 days with an episode of dysphagia (Daily DSQ =2) between
- •Visit 1 and Visit 2.
- •-Must be adherent to daily diary assessments:
- •(a) Must complete 70% of daily diaries between Visit 1 and Visit 2; AND
- •(b) Must have completed at least 8 of 14 daily diaries in the 14 days
- •prior to randomization.
- •-May be on background medications for EoE and related treatments
- •during the study as long as the background medications have been
- •stable for at least 4 weeks (8 weeks for PPI) prior to screening.
- •-Negative serum pregnancy test for female patients of childbearing
- •potential at Visit1.
- •-Women of childbearing potential must agree to use a highly effective
- •form of birth control (confirmed by the Investigator) from randomization
- •throughout the study duration and within 16 weeks after last dose if IP.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 40
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 130
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-Other GI disorders such as active Helicobacter pylori infection, history
- •of achalasia,
- •esophageal varices, Crohn's disease, ulcerative colitis, inflammatory
- •bowel disease, or
- •celiac disease.
- •-Esophageal stricture that prevents the easy passage of a standard
- •endoscope or any critical
- •esophageal stricture that requires dilation during the run-in period.
- •-Esophageal dilation performed within 8 weeks prior to screening.
- •-Use of a feeding tube, or not eating solid food daily during the run-in
- •-Hypereosinophilic syndrome, defined by multiple organ involvement and
- •persistent blood
- •eosinophil count >1500 eos/µL.
- •-EGPA vasculitis.
- •-Eosinophilic gastritis, gastroenteritis, enteritis, or colitis documented by
- •-Current malignancy, or history of malignancy with some specific
- •exceptions.
- •- History of anaphylaxis to any biologic therapy or vaccine.
- •- Current active liver disease:
- •*Chronic stable hepatitis B and C (including positive testing for
- •hepatitis B surface antigen
- •[HBsAg] or hepatitis C antibody), or other stable chronic liver disease
- •are acceptable if patient otherwise meets eligibility criteria.
- •*Alanine aminotransferase (ALT) or aspartate aminotransferase (AST)
- •level =3 times the
- •upper limit of normal (ULN), confirmed by repeated testing during the
- •run-in period.
- •-Helminth parasitic infection diagnosed within 24 weeks prior to the date
- •consent or assent (if applicable) is obtained that has not been treated
- •with or has failed to
- •XML File Identifier: L9b6uobKOJzSkjr7DnEP/7me/Ps=
- •respond to standard of care therapy.
- •-History of known immunodeficiency disorder including a positive human
- •immunodeficiency virus (HIV) test.
- •-Concomitant use of immunosuppressive medication.
- •-Initiation or change of a food-elimination diet regimen or reintroduction
- •of a previously eliminated food group in the 6 weeks prior
- •to start of the run-in period.
- •-Currently pregnant, breastfeeding, or lactating women.
研究者
相似试验
已完成
3 期
Study to evaluate the efficacy (effect on disease) and safety of finerenone on morbidity (events indicating disease worsening) and mortality (death rate) in participants with heart failure and left ventricular ejection fraction (proportion of blood expelled per heart stroke) greater or equal to 40%JPRN-jRCT2080225274Bayer Yakuhin, Ltd.5,500
进行中（未招募）
1 期
A Study of Benralizumab in Patients with Eosinophilic EsophagitisEosinophilic Esophagitis (EoE)MedDRA version: 20.1Level: LLTClassification code 10064220Term: Eosinophilic esophagitisSystem Organ Class: 100000004856EUCTR2019-002871-32-ESAstraZeneca AB210
进行中（未招募）
1 期
A Study of Benralizumab in Patients with Eosinophilic EsophagitisEUCTR2019-002871-32-DEAstraZeneca AB170
进行中（未招募）
不适用
A clinical trial to study the safety and effectiveness of three different strengths (0.03%, 0.1% and 0.3%) bimatoprost solution compared to a solution containing no active ingredient (placebo) and an already licenced product (minoxidil 5%) in the treatment of male-pattern baldness (androgenic alopecia).Androgenic alopecia in menMedDRA version: 14.0Level: LLTClassification code 10068558Term: Androgenic alopeciaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2011-000379-15-DEAllergan Ltd.300
进行中（未招募）
1 期
A Study of Benralizumab in Patients with Eosinophilic EsophagitisEUCTR2019-002871-32-ITASTRAZENECA AB210